Friday 1st July 2022
|Text too small?|
Yesterday, Rua Bioscience’s (NZX: RUA ) partner, Cann Group (ASX: CAN), was granted a GMP licence to manufacture therapeutic goods which includes GMP testing at its Mildura facility.
In combination with the licences and permits issued by the Office of Drug Control (ODC) of Australia earlier this year, the Mildura GMP Licence enables Cann to manufacture Active Pharmaceutical Ingredients (API) and hard capsules and to conduct GMP-approved activities at the facility’s existing chemistry and microbiology laboratories.
Cann is Rua’s Australian strategic manufacturing, supply and technical services partner as a result of Rua’s purchase of Zalm Therapeutics.
Cann’s new AUD $120m cultivation and processing facility at Mildura is considered one of the largest and most advanced in Australasia. The first stage of its construction is now operational and capable of producing 12,500 kilograms of dried cannabis flower per year. When complete, capacity at the 13.5-hectare facility will grow up to 70,000 kilograms. In a capital-light strategy, Gisborne-based Rua is leveraging this scale to deliver a range of medicinal cannabis products to multiple export markets.
No comments yet
Deferral of FDA consideration of enforcement discretion
MHJ - Response to ASX Query
CDI 2022 Interim Results
August 10th Morning Report
TWL - Resignation of Chief Operating Officer
NZA - Funding arrangements following Board changes
August 9th Morning Report
August 8th Morning Report
BIF - Potential material valuation increase for the fund
Nominations open for Fonterra Board of Directors' Election